We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients.
Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them.
We know that together we are better.
Immunology Innovation Program (IIP)
The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic collaborators with our unparalleled experience as antibody engineers.
Co-creation has led to a deep pipeline of highly differentiated product candidates.
Through the IIP, we hope to together transcend breakthrough research and publications to our ultimate and unifying mission of creating new potential treatment options for patients.
An Innovation Ecosystem
"Stepping into these strategic, academic, industry collaborations. This is a wonderful ecosystem that we are creating, by bringing that expertise together.”
Prof. Bart Lambrecht
Structuring our pipeline growth
Innovation and co-creation are at the core of our strategy. We integrate our unique antibody engineering capabilities with the deep disease and target biology expertise of our collaborators. By innovating at the discovery level, we have built a broad pipeline of differentiated potential immunology solutions to offer patients.
We innovate at both the variable region or V region (where antigens and foreign proteins are recognized) and the constant region or Fc region (where antibodies modulate other cells in the immune system):
Suite of Technologies
SIMPLE Antibody™ is argenx's proprietary platform designed to source V regions from the immune system of "outbred" llamas.
Deep relationships power the core of our innovation ecosystem, it is a system of co-creation.
The Immunology Innovation Program is based on mutual respect for the expertise that each partner brings. Our research collaborators bring unique knowledge of disease biology or a disease pathway. argenx can offer antibody engineering capabilities and a path to turn an immunology breakthrough into a clinical development candidate.
We together with our partners have the potential to create differentiated medicines for patients.
For more information on partnering opportunities, please contact:
Arjen Lemmen, Vice President, Corporate Development & Strategy
argenx respects your privacy
Personal information is never kept longer than necessary. Personal data is not provided to third parties without permission or used for marketing purposes.